Site Selection in Clinical Research: How Sponsors Pick the Right Investigative Sites
Every clinical trial depends on a decision made long before the first patient signs a consent form: which investigative sites will run the study. Site selection is the process of identifying, evaluating, and qualifying the research sites that can execute a protocol safely and effectively. Get it right, and enrollment moves on schedule and the data holds up under scrutiny. Get it wrong, and the study bleeds money, months, and credibility.
The Clarity Clinical Solutions training module on advanced site selection argues that poor site choice is one of the most frequently cited root causes of trial delays and failures. Underperforming sites drain sponsor resources, compromise data quality, and stretch timelines. Well-selected sites hit enrollment targets, produce clean data, and strengthen the evidence package that goes to regulators. The choice also shapes patient recruitment, retention, and compliance, which means it shapes the odds of approval.
Feasibility: the data-driven first step
Feasibility assessment comes first. It answers one question: can this site actually run the protocol? Sponsors look at therapeutic expertise, access to the target patient population, trained staff, and whether the equipment and facilities match the study's demands. A serious feasibility review also weighs competing trials at the same site, historical enrollment rates, and the site's track record in similar therapeutic areas.
Feasibility is not guesswork. A site can be fully equipped and staffed, but if the right patients are not within reach, enrollment will fail. Site selectors study epidemiological data, referral patterns, and the demographics of the surrounding area to estimate the potential participant pool. They also think about geography. Regulators expect trial populations to reflect the real-world distribution of the disease, and the FDA has issued guidance asking sponsors to plan for diverse enrollment when designing their trials (FDA Guidance: Enhancing the Diversity of Clinical Trial Populations). Sites near major medical centers, specialty clinics, and underserved communities each bring something different to the table.
The principal investigator carries the study
The principal investigator is the clinical leader of the trial at the site. A qualified PI needs relevant therapeutic expertise, enough time to supervise the study, a clean regulatory record, and the ability to manage the research team. Sponsors review publication history, prior trial experience, inspection history, and any disciplinary actions.
This is not just good practice; it is a regulatory requirement. Under 21 CFR 312.53, the FDA requires sponsors to select investigators who are qualified by training and experience to conduct the study (21 CFR 312.53 — Selecting investigators and monitors). The same principle runs through the ICH E6 good clinical practice guidelines, which hold sponsors responsible for choosing appropriately qualified investigators (ICH E6(R2) Good Clinical Practice). An engaged, experienced PI is the single strongest predictor of site success.
Infrastructure: can the site handle the protocol?
The physical setup has to support the study. Does the site have adequate examination rooms, temperature-controlled drug storage, centrifuges, freezers, and backup power? Is there a dedicated research coordinator? How is the pharmacy set up for investigational product management? Sponsors run facility assessments, sometimes by questionnaire and sometimes in person, to confirm the site can handle the specific demands of the protocol. Specialized trials may need imaging capabilities, infusion suites, or lab certifications that not every site has.
Regulatory history is non-negotiable
Sponsors check FDA Form 483 inspection records, warning letters, and any debarment or disqualification proceedings involving the site or its key people. Sites with repeated findings on informed consent, adverse event reporting, or record keeping represent unacceptable risk. The FDA publishes warning letters and inspection classification data publicly, so sponsors can review a site's history before committing (FDA Warning Letters, FDA Inspection Classification Database).
Institutional review board status matters too. The site needs an active, properly constituted IRB, or access to a central IRB that can review the protocol within workable timelines.
Recruitment plans must be realistic
A common pitfall is taking optimistic enrollment projections at face value. Experienced sponsors require a detailed recruitment plan, not a promise of "20 patients per month." The plan should name specific channels: physician referrals, database mining, community outreach, digital advertising, patient advocacy groups, with realistic conversion rates for each. Historical enrollment velocity from the site's prior trials in similar indications is the most reliable predictor. A site that cannot explain how it will find patients is a red flag.
Questionnaires, visits, and scoring
The site selection questionnaire is the standardized tool sponsors use to gather comparable data across candidates. It covers institutional demographics, therapeutic experience, staff qualifications, patient volume estimates, equipment inventories, and past trial performance. Modern questionnaires increasingly ask about diversity and inclusion plans, electronic data capture capability, and telemedicine readiness.
Questionnaires give structure, but the pre-study visit adds the human dimension. A sponsor representative tours the facility, meets the PI and key staff, watches how work flows, and gets a feel for the site's culture. These visits often expose what paperwork hides: cramped storage, disorganized files, a PI who looks overcommitted.
Most sponsors then rank candidates with a formal scoring framework. Variables like therapeutic expertise, recruitment potential, regulatory history, and infrastructure get weighted to the protocol's needs. Some sponsors use predictive analytics built on historical performance data from thousands of sites to forecast enrollment curves. The goal is a balanced portfolio: high-performing anchor sites plus diverse community sites, not just the strongest individual performers.
Global trials add another layer
Multinational studies bring country-level regulatory timelines, import and export restrictions on investigational product, cultural considerations around consent, and different standards of care. Sponsors weigh established hubs against emerging regions, balancing enrollment speed, data acceptance by regulators, and cost. A balanced global portfolio optimizes quality, speed, and cost at the same time.
Mistakes that repeat
Even experienced sponsors slip. They pick sites based on personal relationships rather than data. They overestimate enrollment at academic medical centers where patients are spread across many studies. They skip checking whether staff will actually be available for the full study. They ignore the cumulative burden of multiple ongoing trials at one site. And some select too many sites to compensate for weak feasibility, which dilutes enrollment, raises monitoring costs, and produces worse results than a focused portfolio.
The bottom line
Site selection is not a transactional checkbox. It is a strategic process that sets the trajectory of the whole clinical program. Start with rigorous feasibility, weigh both quantitative metrics and qualitative factors, verify regulatory compliance and infrastructure, demand realistic recruitment plans, and score sites objectively. A well-chosen site enters activation with a strong foundation, ready to enroll quickly and produce quality data. Every stage of the trial that follows builds on that groundwork.
This article is based on the Clarity Clinical Solutions video "Advanced Site Selection: Understanding Sites in Clinical Research." Watch it here: Advanced Site Selection: Understanding Sites in Clinical Research
References
- Clarity Clinical Solutions — "Advanced Site Selection: Understanding Sites in Clinical Research" (framework for this article). https://www.youtube.com/watch?v=fXWBz0S-zhY
- ICH — E6(R2) Good Clinical Practice guideline; sponsor responsibility to select qualified investigators. https://www.ich.org/page/e6r2
- eCFR — 21 CFR 312.53; FDA requirement that sponsors select investigators qualified by training and experience. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-D/section-312.53
- FDA — Guidance for Industry: Enhancing the Diversity of Clinical Trial Populations; regulator expectations on representative trial populations. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial
- FDA — Warning Letters database; public record of enforcement communications. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
- FDA — Inspection Classification Database; public record of inspection outcomes. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-classification-database